New triple therapy aims to tame tough diabetes

NCT ID NCT07244003

Recruiting now Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Dec 08, 2025 · Last updated Jun 18, 2026 · Updated 34 times

Summary

This study tests a combination of three diabetes drugs (metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist) versus other oral medications in adults with type 2 diabetes who have poor blood sugar control. The goal is to see which combo works better at lowering blood sugar, blood pressure, and cholesterol. About 430 participants aged 18-75 will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tianjin Medical University General Hospital
RECRUITING

Tianjin, Tianjin Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T2DM (TYPE 2 DIABETES MELLITUS) T2DM (TYPE 2 DIABETES MELLITUS)